Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aslan Pharmaceuticals Ltd ASLN

Healthcare Biotechnology
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness... see more

Recent & Breaking News (NDAQ:ASLN)

ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis

GlobeNewswire June 7, 2022

ASLAN Pharmaceuticals to Host Third Webinar in A⁴ KOL Series: 'Dialogues With International Thought Leaders in Dermatology'

GlobeNewswire June 6, 2022

ASLAN Pharmaceuticals to Participate in Fireside Chat at Jefferies Global Healthcare Conference

GlobeNewswire May 31, 2022

ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting

GlobeNewswire May 20, 2022

ASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 18, 2022

ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation at the 2022 Society for Investigative Dermatology Annual Meeting

GlobeNewswire May 10, 2022

ASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire April 27, 2022

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022

GlobeNewswire April 6, 2022

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

GlobeNewswire April 1, 2022

ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting

GlobeNewswire March 28, 2022

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 25, 2022

ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting

GlobeNewswire March 18, 2022

ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer

GlobeNewswire March 15, 2022

ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis

GlobeNewswire January 20, 2022

ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004

GlobeNewswire January 18, 2022

ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology Conferences

GlobeNewswire January 11, 2022

ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022

GlobeNewswire January 6, 2022

ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration

GlobeNewswire December 6, 2021

ASLAN Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

GlobeNewswire November 22, 2021

ASLAN Pharmaceuticals to Participate in Fireside Chat at the 12th Annual Jefferies London Healthcare Conference 2021

GlobeNewswire November 10, 2021